## EG: Everest Group, Ltd. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -4.0% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($296.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Global: Everest Group announces new appointments**
- Source: Asia Insurance Review | 20251205T000512 | Bullish | Relevance: 100%
- Everest Group has announced the appointments of Mr. Attila Kerényi as Group Chief Risk Officer and Ms. Katy Bradica as Group Chief Actuary, both effective early 2026. Mr. Kerényi will lead the global enterprise risk management function, while Ms. Bradica will oversee the global actuarial function, focusing on pricing, reserving, and analytics. These strategic appointments aim to strengthen Everest's risk strategy, governance, and capital efficiency.

**2. Everest Announces Key Leadership Appointments**
- Source: Business Wire | 20251203T212150 | Bullish | Relevance: 100%
- Everest Group, Ltd. announced the appointments of Katy Bradica as Group Chief Actuary and Attila Kerényi as Group Chief Risk Officer, both effective early 2026. These leadership additions are intended to strengthen the company's underwriting excellence and risk management, enhancing its competitive position and long-term shareholder value. The article highlights their extensive experience in actuarial science and risk management within global financial services.

**3. Everest Group (NYSE: EG) names new chief actuary and chief risk officer for 2026**
- Source: Stock Titan | 20251203T211500 | Bullish | Relevance: 100%
- Everest Group, Ltd. (NYSE: EG) has announced two key leadership appointments effective early 2026: Katy Bradica as Group Chief Actuary and Attila Kerényi as Group Chief Risk Officer. Ms. Bradica will lead global actuarial functions, while Mr. Kerényi will oversee global Enterprise Risk Management, strengthening the company's underwriting, risk foundation, and capital resilience. These appointments aim to enhance Everest's competitive position and drive long-term shareholder value.

**4. Everest Group (EG): Evaluating Valuation After Appointing Veteran Finance Leader Elias Habayeb as New CFO**
- Source: Simply Wall Street | 20251203T120221 | Somewhat-Bullish | Relevance: 100%
- Everest Group (EG) has appointed Elias Habayeb as its new CFO, a move that prompts a re-evaluation of the company's valuation. Despite recent share price declines, the consensus suggests EG is undervalued with a fair value estimate of $368.86 against a last close of $312.21, driven by ongoing investments and expected margin improvements. However, increased catastrophe exposure and high expenses pose risks to this valuation.

**5. Everest Group names new CFO as Mark Kociancic plans retirement and transition By Investing.com**
- Source: Investing.com Australia | 20251203T083600 | Neutral | Relevance: 100%
- Everest Group, Ltd. announced that its Executive Vice President and CFO, Mark Kociancic, will retire following the company’s first-quarter 2026 reporting cycle. Elias Habayeb is set to take over as Executive Vice President and Chief Financial Officer around May 1, 2026. Kociancic will remain as a special advisor through July 31, 2026, and is eligible for substantial compensation and benefits during his transition and separation.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (-1.0%)
- Blackrock Inc.: 8.1% (-2.9%)
- AQR Capital Manageme: 4.8% (+70.3%)
- State Street Corpora: 4.5% (-0.7%)
- Vulcan Value Partner: 3.4% (+13.9%)

### Key Risks

1. Long-term trend broken: trading 9.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 5.6x attractive for 24% earnings growth. Balance sheet: strong liquidity (11.3x). Revenue declining -7% YoY, concerning. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 0.38 |
| 52W Range | $302.44 - $373.23 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -50.00 |
| Forward P/E | 5.6 |
| Current P/E | 6.9 |
| YoY Growth | 24.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.4% to -4.0% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). Underperforming sector by 3.7pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (0.58), confirming momentum. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.04% (CS: 17) | Weak |
| RSI_14 | 39.5 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.935x | Below |
| vs SMA200 | 0.910x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $309.97
- **Stop Loss:** $296.47 (4.4% risk)
- **Target:** $323.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $22,937.78
- **Portfolio %:** 22.94%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-02 (Est: $13.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $14.52 | $7.54 | -48.1% |
| 2025Q2 | $14.82 | $17.36 | +17.1% |
| 2025Q1 | $7.74 | $6.45 | -16.7% |
| 2024Q4 | $-17.42 | $-18.39 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*